| Title: |
Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo |
| Authors: |
Newby, D E; Witherow, F N; Wright, R A; Bloomfield, P; Ludlam, C A; Boon, N A; Fox, K A A; Webb, D J |
| Publisher Information: |
British Medical Journal Publishing Group |
| Publication Year: |
2002 |
| Collection: |
HighWire Press (Stanford University) |
| Subject Terms: |
Cardiovascular medicine |
| Description: |
Objective: To assess acute tissue plasminogen activator (t-PA) release in vivo in patients with hypercholesterolaemia in the presence and absence of lipid lowering treatment and in matched normocholesterolaemic controls. Design: Parallel group comparison and double blind randomised crossover. Setting: University hospital. Patients: Eight patients with hypercholesterolaemia (> 7.8 mmol/l) and eight matched normocholesterolaemic controls (< 5.5 mmol/l). Methods: Blood flow and plasma fibrinolytic factors were measured in both forearms during unilateral brachial artery infusions of the endothelium dependent vasodilator substance P (2–8 pmol/min) and the endothelium independent vasodilator sodium nitroprusside (1–4 μg/min). Interventions: In patients, measurements were made on three occasions: at baseline and after six weeks of placebo or pravastatin 40 mg daily administered in a double blind randomised crossover design. Main outcome measures: Acute release of t-PA. Results: Compared with patients, in normocholesterolaemic control subjects substance P caused greater dose dependent increases in forearm blood flow (p < 0.05) but similar increases in plasma t-PA antigen and activity concentrations. During pravastatin treatment in patients, total serum cholesterol fell by 22% from a mean (SEM) of 8.1 (0.3) to 6.4 (0.4) mmol/l (p = 0.002) and substance P induced vasodilatation was no longer significantly impaired in comparison with controls. However, despite reproducible responses, pravastatin treatment was not associated with significant changes in basal or substance P induced t-PA release. Conclusions: Hypercholesterolaemia and lipid lowering treatment cause no demonstrable effects on acute substance P induced t-PA release in vivo. This suggests that the preventative benefits of lipid lowering treatment are unlikely to be mediated by improvements in endogenous fibrinolysis. |
| Document Type: |
text |
| File Description: |
text/html |
| Language: |
English |
| Relation: |
http://heart.bmj.com/cgi/content/short/87/1/48; http://dx.doi.org/10.1136/heart.87.1.48 |
| DOI: |
10.1136/heart.87.1.48 |
| Availability: |
http://heart.bmj.com/cgi/content/short/87/1/48; https://doi.org/10.1136/heart.87.1.48 |
| Rights: |
Copyright (C) 2002, BMJ Publishing Group Ltd |
| Accession Number: |
edsbas.39031DDD |
| Database: |
BASE |